Rosetta Genomics Announces Expansion of its Research Facility
News Jul 18, 2007
Rosetta Genomics Ltd has announced the expansion of its Israeli research facility. The company is adding the new laboratories to its facilities in order to meet its research and development needs for its microRNA-based diagnostic programs. The company expects to grow to approximately 70 employees by the end of the year.
"This expansion will enable us to advance new development programs, and accommodate the large number of scientists that have joined Rosetta recently and those we expect to add in the future," said Amir Avniel, Rosetta Genomics' Chief Executive Officer.
Mr. Avniel continued, "Our proprietary discovery platform is capable of utilizing over twelve thousand predicted and validated microRNAs, including over 1000 proprietary microRNAs, which are expressed in different tissues. This platform provides us with the foundation upon which we can advance microRNA-based diagnostic products in key oncology indications. The new lab space is essential for the success of these efforts."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.